Clinical trial
Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer…
NCT00411593 · M.D. Anderson Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00411593 |
|---|---|
| Title | Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC) |
| Official title | Phase I-II Study of Avastin®+ Bortezomib for Patients With Recurrent or Refractory Non-Squamous NSCLC |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry Genentech, Inc. |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Bortezomib |
| Enrollment | 0 |
| Start date | Nov 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Dec 14, 2006 |
| Last update posted | Feb 8, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: